Status and phase
Conditions
Treatments
About
This study is a phase 2 multinational, multicenter, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of SP-02L monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Patients with a Japanese, Korean, Taiwanese, or Chinese ethnic background of each country/region
Patients aged ≥20 years on the date of informed consent
Patients with histologically confirmed diagnosis of one of the following:
Relapsed or refractory patients with a treatment history of at least one regimen with antitumor agents for the above disease
Have at least 1 measurable lesion
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Patients with a life expectancy of at least 3 months as determined by the investigator
Primary purpose
Allocation
Interventional model
Masking
67 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal